(Q51964774)

19 April 2018

title

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. (English)

1 reference

19 April 2018

0 references

8

1 reference

19 April 2018

Valentina Tomassini

1

object named as

Valentina Tomassini

1 reference

19 April 2018

Andrea Paolillo

2

1 reference

19 April 2018

Pierluigi Russo

3

1 reference

19 April 2018

Elisabetta Giugni

4

1 reference

19 April 2018

Luca Prosperini

5

1 reference

19 April 2018

Claudio Gasperini

6

1 reference

19 April 2018

Guido Antonelli

7

1 reference

19 April 2018

Carlo Pozzilli

9

1 reference

19 April 2018

publication date

14 September 2005

1 reference

19 April 2018

published in

Journal of Neurology

1 reference

19 April 2018

volume

253

1 reference

19 April 2018

issue

3

1 reference

19 April 2018

page(s)

287-293

1 reference

19 April 2018

https://scigraph.springernature.com/pub.10.1007/s00415-005-0979-5

exact match

0 references

cites work

Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG).

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0979-5

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0979-5

MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0979-5

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0979-5

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0979-5

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-005-0979-5

WHO Expert Committee on Biological Standardization. Thirty-fifth report

21 January 2018

1 reference

12 December 2020

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

1 reference

12 December 2020

Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques.

1 reference

12 December 2020

Defining interferon beta response status in multiple sclerosis patients.

1 reference

12 December 2020

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

1 reference

12 December 2020

Quantitation of neutralization of interferon by antibody

1 reference

12 December 2020

Effects of interferon-beta on steroid receptors, prostaglandins and enzymatic activities in human endometrial cancer.

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Changes in cytokine production of breast cancer patients treated with interferons

1 reference

12 December 2020

Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

12 December 2020

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

1 reference

12 December 2020

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

1 reference

12 December 2020

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Determinants of Gd-enhanced MRI response to IFN-beta-1a treatment in relapsing-remitting multiple sclerosis.

1 reference

12 December 2020

The role of MRI as a surrogate outcome measure in multiple sclerosis

1 reference

12 December 2020

A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.

1 reference

12 December 2020

Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.

1 reference

12 December 2020

Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

1 reference

12 December 2020

Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events

1 reference

12 December 2020

Interferon beta1a (Avonex) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disability

1 reference

12 December 2020

Clinical characteristics of responders to interferon therapy for relapsing MS.

1 reference

12 December 2020

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

1 reference

12 December 2020

Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability

1 reference

12 December 2020

The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit

1 reference

12 December 2020

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

1 reference

12 December 2020

Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.

1 reference

12 December 2020

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a

1 reference

12 December 2020

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up.

1 reference

12 December 2020

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

12 December 2020

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

1 reference

12 December 2020

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

1 reference

12 December 2020

'Gender gap' in multiple sclerosis: magnetic resonance imaging evidence.

1 reference

12 December 2020

10.1007/S00415-005-0979-5

Identifiers

DOI

1 reference

19 April 2018

PubMed ID

16151600

1 reference

19 April 2018